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Abstract
Introduction: Increasing evidence supports the view that the detection of circulating tumor cells (CTCs) predicts
outcomes of nonmetastatic breast cancer patients. CTCs differ genetically from the primary tumor and may
contribute to variations in prognosis and response to therapy. As we start to understand more about the biology
of CTCs, we can begin to address how best to treat this form of disease.
Methods: Ninety-eight nonmetastatic breast cancer patients were included in this study. CTCs were isolated by
immunomagnetic techniques using magnetic beads labelled with a multi-CK-specific antibody (CK3-11D5) and CTC
detection through immunocytochemical methods. Estrogen receptor, progesterone receptor and epidermal growth
factor receptor (EGFR) were evaluated by immunofluorescence experiments and HER2 and TOP2A by fluorescence
in situ hybridization. We aimed to characterize this set of biomarkers in CTCs and correlate it with clinical-
pathological characteristics.
Results: Baseline detection rate was 46.9% ≥ 1 CTC/30 ml threshold. CTC-positive cells were more frequent in
HER2-negative tumors (p = 0.046). In patients younger than 50 years old, HER2-amplified and G1-G2 tumors had a
higher possibility of being nondetectable CTCs. Heterogeneous expression of hormonal receptors (HRs) in samples
from the same patients was found. Discordances between HR expression, HER2 and TOP2A status in CTCs and their
primary tumor were found in the sequential blood samples. Less that 35% of patients switched their CTC status
after receiving chemotherapy. EGFR-positive CTCs were associated with Luminal tumors (p = 0.03).
Conclusions: This is the largest exploratory CTC biomarker analysis in nonmetastatic BC patients. Our study
suggests that CTC biomarkers profiles might be useful as a surrogate marker for therapeutic selection and
monitoring since heterogeneity of the biomarker distribution in CTCs and the lack of correlation with the primary
tumor biomarker status were found. Further exploration of the association between EGFR-positive CTCs and
Luminal tumors is warranted.
Introduction
Breast cancer (BC) is the most frequently diagnosed
malignancy in women [1]. Despite considerable advances
in early detection, diagnosis, and treatment, BC is
among the leading causes of cancer-related deaths in
women because of recurrent metastatic disease.
Understanding the molecular profile of BC is becom-
ing ever more relevant to patient care. Molecular sub-
types were first described by Perou and colleagues [2,3],
who mapped the phenotypic diversity to a specific gene
expression pattern. An immunohistochemistry (IHC)
profile based on the degree of expression of estrogen
receptor (ER), progesterone receptor (PR), and human
epithelial growth factor receptor 2 (HER2) similarly
identifies subgroups of BC patients who will have similar
gene expression patterns and clinical outcomes [3-5].
Subsequently, subgroups (within major groups) that
have been defined as ER-, PR-, and HER2- tumors that
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express cytokeratin (CK) 5/6 proteins or epidermal
growth factor receptor (EGFR) or both represent
another distinctive BC tumor subtype known as the core
basal phenotype, which is associated with a worse prog-
nosis [6]. Moreover, EGFR is considered essential in
cancer cell migration and the intravasation process [7,8].
Therefore, we were interested in exploring the expres-
sion of EGFR in circulating tumor cells (CTCs) of
patients with BC.
Subsequent studies showed differences in prognosis
and differences in their response to therapeutic agents
with respect to the subtype in specific cohorts of
patients [4,5]. In addition to clinical and pathological
factors currently used to guide prognosis and treatment,
new evidence regarding the association of topoisomerase
2a (TOP2A) gene alterations and an increase in respon-
siveness to antracycline-containing regimens has been
reported [9,10]. However, no studies have evaluated the
TOP2A status in CTCs. These biomarker profiles do not
guarantee a response to systemic therapy, and a fraction
of patients will receive the established or investigational
therapies without deriving any benefit. The presence of
CTCS in the peripheral blood of non-metastatic BC
patients has been associated with worse clinical out-
comes [11-13]. In addition, there is increasing evidence
of discrepancies between ER, PR, and HER2 expression
in CTCs and the corresponding primary tumors, raising
concern about the clinical implications of these observa-
tions[14-17]. Thus, the need to determine prognostically
and therapeutically relevant markers in minimal residual
disease is becoming important in order to increase per-
sonalized treatment options [18].
In this work, we sought to evaluate ER, PR, and EGFR
expression and HER2 and TOP2A status in CTCs in a
non-metastatic BC population. We further correlated
the CTC findings with clinical and pathological charac-
teristics of primary tumors and the distinct BC subtypes.
Materials and methods
From March 2009 to September 2010, patients with
stage I to IIIC BC were identified from the Breast Can-
cer Unit at the Hospital del Mar and Hospital Universi-
tario de Jaén. The inclusion criteria were histological
diagnosis of BC and availability of tissue for biomarker
studies. Surgical procedure and systemic therapy were
selected at the discretion of the treating physician with
or without targeted therapy (namely, trastuzumab) for
patients with HER2+ BC. Medical charts of these
patients were reviewed, and clinical details of these
patients were included in a database.
A total of 98 patients donated three samples of 10 mL
of blood at the time of first diagnosis. If adjuvant ther-
apy (AT) was administered, post-treatment samples
were obtained after three cycles of chemotherapy. If
neoadjuvant therapy (NAT) was administered, samples
were obtained at the end of treatment. For this study,
we classified BC patients based on the pattern of expres-
sion of the hormone receptor (HR), estrogen and pro-
gesterone receptor, and HER2 status that identify three
major distinct molecular BC subtypes [2,3]: luminal
tumors, which are HR+ and HER2-; HER2-amplified
tumors; and those tumors that lack expression of the
three receptors, known as triple-negative BC. This trans-
lational study was approved by the ethics review com-
mittees of the Hospital del Mar and Hospital de Jaén,
and informed consent was obtained from all patients
and healthy volunteers.
Assessment of tumor biomarkers
Tumor specimens from archival tumor biopsies were
available for HER2 and TOP2A status (n = 98 and n =
23), ER and PR (n = 98), p53 (n = 65), and Ki-67 (n =
98). ER and PR were routinely assessed by IHC by using
6F11 (diluted 1:40; Novocastra, Newcastle Upon Tyne,
UK) and 312 (diluted 1:100) antibodies, respectively, in
accordance with guidelines of the American Society of
Clinical Oncology/College of American Pathologists
[19]. Ki-67 proliferation index was assessed by using
mouse monoclonal antibody MIB-1 (1:200 dilutions;
Dako, Glostrup, Denmark), and the percentage of posi-
tively stained nuclei was calculated. Samples with any
degree of p53 nuclear staining (clone DO-7; Novocastra
Lab, Newcastle, UK) were considered positive. HER2
status was determined by IHC by using Herceptest
(Dako) in all patients and was confirmed by fluorescence
in situ hybridization (FISH) when indicated - Pathvysion
HER2 DNA Probe Kit from Abbott Molecular (Abbott
Park, IL, USA) in two centers and PharmaDX from
Dako in two centers - in accordance with current
recommendations [20]. TOP2A status was also evaluated
by FISH by using a TOP2A/CEP17 FISH probe kit
(Abbott Molecular Inc., Des Plaines, IL, USA). TOP2A
amplification was considered if the TOP2A/CEP17 ratio
was 2:1 or greater We considered polysomy 17 (p17)
when cells had three or more copy numbers of centro-
meres for chromosome 17 per cell[21].
Isolation and enumeration of circulating tumor cells
Blood (30 mL) was collected from each donor into three
different blood collection tubes (CellSave Preservatives
Tubes; Veridex, LLC, Raritan, NJ, USA), maintained at
room temperature, and processed in parallel within a
maximum of 72 hours after collection in accordance
with the protocol established for our group [22]. Briefly,
the samples were processed by density gradient centrifu-
gation (Histopaque 1119; Sigma-Aldrich, St. Louis, MO,
USA). For CTC enrichment, we used the Carcinoma
Cell Enrichment and Detection kit with MACS
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technology (Miltenyi Biotec, Bergisch Gladbach, Ger-
many). CTC enrichment was performed by selective
immunomagnetic cell separation, using magnetic beads
labeled with a multi-CK-specific antibody (CK3-11D5),
which recognizes CK 7, 8, 18, and 19. CTCs were identi-
fied by immunocytochemical methods and visualized
under a direct light microscope to perform the com-
bined cytomorphological and immunophenotypic assess-
ment. The cytomorphological criteria proposed by Meng
and colleagues [23] (for example, high nuclear/cytoplas-
mic ratio and cells larger than white blood cells) were
used to characterize a CK+ cell as a CTC. As we ana-
lyzed three different tubes of 10 mL in each sample, we
determined a case to be CTC+ if at least one CTC was
isolated in at least one of the three tubes. Therefore,
patients were considered CTC+ if at least one CTC+ was
captured in one tube of 10 ml of blood of the 30 ml of
blood analyzed.
Cell cultures and molecular biomarker assay feasibility
BC cell lines were obtained from the American Type Cul-
ture Collection (Manassas, VA, USA). In the analysis of
recovery experiments, we analyzed control samples with
high-level control numbers (2,000, 100, and 50 cells)
from two human BC cell lines, MCF-7 and SKBR3, and
with low level control numbers (10 and 5 cells and 1 cell)
from four human BC cell lines: MCF-7, SKBR3, MDA-
MB231, and T47D. Cells were spiked in 10 mL of venous
blood from healthy volunteers, and control experiments
were performed at least in triplicate. Cytospins were pre-
pared afterward by density gradient centrifugation and
immunomagnetic selection as per patient’ samples. In
our spiking experiments, recovery rates of tumor cells
spiked into normal blood at the high-level control num-
bers were in the range of 40% to 60% and at the low level
control numbers as shown in Supplementary Table S1 of
Additional file 1. As negative controls, 16 blood samples
from healthy volunteers without evidence of an epithelial
malignancy were examined. Peripheral blood was drawn
from the middle of vein puncture after the first 10-mL of
blood were discarded. This precaution was undertaken in
order to avoid contamination of the sample with epithe-
lial cells from the skin during sample collection and to
ensure a high specificity of the method. No CK+ cells
could be identified in these samples.
We next tested the technical feasibility of using, in
assay, isolated CTCs that are more commonly used for
biomarker assessment: protein expression by immuno-
fluorescence (IF) and DNA amplification by FISH. Posi-
tive controls were created by using decreasing numbers
of cells from BC cell lines spiked in blood from healthy
volunteers, and cytospins were prepared as described
above. For negative controls, blood from healthy volun-
teers was used and the primary antibody was omitted.
We tested whether ER, PR, and EGFR expression
could be accurately determined by IF in CTCs by using
the human BC cell line MCF-7; MDA-MB231 and
SKBR3 as positive controls (Figure 1a). Using an anti-
ER, -PR, and -EGFR antibody, we evaluated the expres-
sion seen in CTCs by the presence or absence of stain-
ing [24]. HER2 and TOP2A gene amplifications of BC
cell lines were determined by FISH by using HER2/
TOP2A/CEP17 probes. Tumor cells from SKBR3 (2,000,
100, and 50 cells) were spiked into whole blood, and
cytospins were prepared under conditions identical to
those of patient samples. Cells were analyzed for HER2
and TOP2A amplification according to standard criteria
as described above for primary tumors. Absolute and
relative copy numbers of HER2 and TOP2A genes in
SKBR3 and MCF-7 cells after immunomagnetic separa-
tion from blood samples and fluorescence immunophe-
notyping and interphase cytogenetics as a tool for
investigation of neoplasms (FICTION) analyses are
shown in Supplementary Table S2 of Additional file 2.
Characterization of ER, PR, and EGFR in circulating tumor
cells
CK+ and EGFR+ cells were identified by IHC, and the
signal was detected by chromogenic and fluorescent
detection, respectively. CK-expressing cells were
revealed by incubation with freshly prepared Fast Red
TR/Naphthol AS-MX substrate solution (Sigma-
Aldrich). Slides were washed once with phosphate-buf-
fered saline and stained with Mayer’s hematoxylin solu-
tion (Sigma-Aldrich). EGFR-expressing cells were
revealed by incubation with primary monoclonal anti-
human EGFR (Dako) diluted 1:25, followed by incuba-
tion with Alexa fluor 355 (Molecular Probes, now part
of Invitrogen Corporation, Carlsbad, CA, USA). Epithe-
lial tumor cells were identified and enumerated on the
basis of their red staining for CK+ cells and blue staining
for EGFR+ cells.
Slides positive for CK+ cells were then stained with ER
and PR rabbit anti-human primary antibodies and after-
ward with the corresponding anti-rabbit secondary antibo-
dies labeled with Alexa fluor 488 for double- or triple-IF
experiments following the laboratory requirements. Speci-
fic staining can easily be distinguished by the differential
intracellular distribution of the examined molecules and
the combination of direct and indirect IF in order to eval-
uate Ck+/ER and CK+/EGFR/PR (Figure 1b, c).
Characterization of HER2 and TOP2A amplification in
circulating tumor cells
HER2 and TOP2A amplification was determined by
FISH. The TOP2A/HER2/CEP17 multi-color probe
includes a TOP2A probe labeled with platinumBright495
(green), HER2 probe labeled with platinumBright550
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(red), and chromosome enumeration probe CEP17
labeled with platinumBright415 (blue) (Kreatech, Dur-
ham, NC, USA) (Figure 1c).
After incubation, dehydratation, and air drying of cells,
slides were co-denatured with the TOP2A/HER2/CEP17
multi-color probe for 5 minutes at 85°C. Hybridization
with the probe previously denatured for 7 minutes at
75°C was performed at 37°C. After different washing
steps, slides were counterstained with 4’-6-diamidino-2-
phenylindole (DAPI) (Vector Laboratories, Burlingame,
CA, USA). After FISH processing, CTCs were re-identi-
fied based on location and Ck+ staining, and nuclei were
scored for copies of HER2, TOP2A, and CEP17 as for
primary tumors.
Identification and counting were done with a compu-
terized fluorescence microscope (Zeiss AXIO Imager;
Carl Zeiss, Jena, Germany). CK+ cells were identified
under a direct light microscope. After CK+ cell detection
<ͲƉŽƐŝƚŝǀĞĞůů͘ '&ZƉŽƐŝƚŝǀĞ ĐŽŶƚƌŽůD&ϳ
ZнͬZͲ ͬ<нdƐ WZнͬ<нƐƉĞĐŝĨŝĐ/&dZнͬ<нƐƉĞĐŝĨŝĐ/&d
͘
͘
ZƉŽƐŝƚŝǀĞĐŽŶƚƌŽůD&ϳ
͘ ,ZϮͬdKWϮĂŵƉůŝĨŝĞĚdƐ'&Zнͬ<нƐƉĞĐŝĨŝĐ/&d
Figure 1 Image galleries of representative biomarker profiles in CTCs. (a) Image galleries after isolation, cytomorphological analysis, and
detection of cytokeratin-positive (CK+) cells (red staining), estrogen receptor (ER), and epidermal growth factor receptor (EGFR) in MCF7 cell
tumor lines. (b) Expression of different markers in patients with breast cancer through combination of stained CK+ cells (red) with ER or
progesterone receptor (PR) (blue). ER- and PR-specific immunofluorescence (IF) of circulating tumor cells (CTCs) was determined with Alexa 355.
ER-specific IF of CTCs of a heterogeneous case is shown. (c) EFGR protein expression was detected by immunocytochemistry by using anti-
human-EGFR antibodies (blue). EGFR-specific IF of CTCs was determined with Alexa 355. Human epidermal growth factor receptor 2 (HER2) and
topoisomerase 2a (TOP2A) gene amplification was determined by fluorescence in situ hybridization (FISH) assay before immunophenotyping
with anti-CK antibody (green). Image demonstrates HER2 amplification (red dots) and TOP2A amplification (green dots) compared to centromere
17 (CEP17; blue dots) in CTCs.
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in each tube independently, samples were brought to
fluorescence light to evaluate cells with expression of
CK+/EGFR/RP, CK+/ER, and CK+/HER2 and TOP2A
status.
Statistical methods
The main objectives were to investigate the status of five
biomarkers in CTCs of patients with BC and to corre-
late this findings with clinical-pathological parameters
and BC subtypes. Secondary objectives were to test
changes in CTC count between inclusion and sequential
samples, to evaluate the group of BC patients with non-
detectable CTCs, and to evaluate the efficiency of pro-
cessing three tubes with 10 mL of blood in terms of
CTC count and biomarker assessment. The presence of
at least one CTC per 10 mL was considered a positive
result according to the reported analytic detection limit
of our assay [22].
The statistical analysis was performed by using SPSS
14.0 software (SPSS Inc., Chicago, IL, USA). Data are
expressed as means or numbers (percentages). Categori-
cal variables were compared by Fisher exact test, and
continuous variables were compared by Student t test.
Two-tailed P values of less than 0.05 were considered
statistically significant. Odds ratios (ORs) for the logistic
model were calculated with their 95% confidence inter-
vals (CIs) to assess the association between clinical-
pathological variables and the CTC status.
Results
Detection of circulating tumor cells
Ninety-eight patients with BC were enrolled in our
study. Before systemic treatment, we identified CTCs in
46 out of 98 patients (46.9%). For patients in whom
CTCs were detected, the mean number of CTCs present
was 3.4 cells per 30 mL of blood (range of 1 to 19).
After three cycles of AT, CTCs were identified in 13 out
of 38 patients (34.2%), and the mean value was 2.6 cells
per 30 mL (range of 1 to 7). At the end of NAT, CTCs
were detected in 16 out of 35 patients (45.7%). The
mean CTC count was 2.6 cells per 30 mL in peripheral
blood (range of 1 to 9). In a direct comparison of the
incidence of CTC detection at baseline versus the
sequential blood samples, no significant differences were
found (P = 0.30 and P = 0.39, respectively).
Distribution of CTC+ samples in the three tubes col-
lected and stratification according to the CTC count are
shown in Figures 2a and 2b. In the baseline samples, in
56.5% of the patients, we were able to evaluate one of
these phenotypes: CK+/ER, CK+/EGFR/RP, or CK
+/HER2/TOP2A; in 28.3% of the patients, we were able
to evaluate two of them. Although a large amount of
blood was analyzed for each patient, we were able to
evaluate the whole set of biomarkers in less than 16% of
the patients at any time point. Additionally, in approxi-
mately 80% of CK+ samples, four CTCs or fewer were
captured to perform the biomarker analysis.
Clinical-pathological characteristics and circulating tumor
cell status
The patients’ characteristics are consistent with those of
an unselected early and locally advanced BC population.
Main chemotherapy regimens included antracyclines
(66.3%), taxanes (54.1%), cyclophosphamide (100%), and
5-fluorouracil (66.3%). Trastuzumab was administered
only to patients with HER2+ tumors (14.3%). Addition-
ally, 72.4% of patients with HR+ received endocrine
therapy with letrozole (44.8%), tamoxifen (23.4%), or
tamoxifen (2 to 3 years) followed by exemestane (4.1%).
Clinical-pathological characteristics with stratification
according to the baseline CTC status are described in
Table 1. Three of the 14 patients with HER2-amplified
primary tumors showed CTCs+, whereas in the remain-
ing 11 patients with HER2 amplification, we did not
detect CTCs (P = 0.046). In contrast, no significant cor-
relation was found between CTC status and other clini-
cal characteristics of patients.
We attempted to look at the patients with undetect-
able CTCs in all of their analyzed blood samples and
CTCs were not detectable in 43 (43.9%) patients. There
was no statistical association between undetectable CTC
status and tumor size, node status, histology, HR, Ki-67
and p53 status, or surgical procedures. However, we
observed that a higher probability of patients with unde-
tectable CTCs was recorded in patients who were
younger than 50 years old (OR = 1.04, 95% CI = 1.01 to
10.8, P = 0.02) and had G1-G2 (OR = 6.9, 95% CI =
1.72 to 27.79, P = 0.006) or HER2-amplified (OR = 0.21,
95% CI = 0.05 to 0.84, P = 0.02) tumors.
Hormonal status of circulating tumor cells and
corresponding primary tumors
ER expression was evaluated before any systemic treat-
ment, and ER staining was detected in 10 (50%) of the
CK+ CTC samples. Heterogeneity for ER expression was
found in five of 10 (50%) patients with ER+ CTCs;
hence, ER+ and ER- CTCs were coexisting in the same
sample. Among 13 patients with ER+ tumors, CTCs
detected before systemic therapy were analyzed for ER
expression. As we expected, eight (61.5%) of these
patients were classified as having ER+ CTCs whereas
five (38.5%) of them had ER- CTCs.
PR status in CTCs was analyzed in 27 CTC+
patients, and nine (33%) had significant nuclear PR
expression. Heterogeneity for PR expression was
found in one (11.1%) patient. When the PR expression
was correlated between CTCs and their corresponding
primary tumors, CTCs from 15 (68.2%) RP+ primary
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tumors were classified as PR- CTCs. In contrast, only
seven (31.8%) patients with PR+ tumors also had PR+
CTCs. It is worth noting that there was no complete
correlation between ER and PR expression in CTCs
and their corresponding primary tumors, respectively
(P = 0.17 and P = 0.55). Moreover, ER and PR status
in CTCs did not show an association with clinical-
pathological baseline characteristics of patients (data
not shown).
EGFR expression in circulating tumor cells
At baseline, EGFR+ CTCs were detected in 27 (27.5%)
patients. After three cycles and at the completion of
chemotherapy, we detected EGFR+ CTCs in five (13.9%)
and four (11.1%) of the patients, respectively. No signifi-
cant correlation was found between basal EGFR-CTC
status and clinical-pathological characteristics of
patients, including age, tumor size, nodal status, histol-
ogy, nuclear tumor grade, p53 status, and Ki-67 and
HER2 status. Remarkably, a higher proportion of
patients with EGFR+ CTCs was found in HR+ patients
(33.3% versus 8.7%, P = 0.01).
HER2 and TOPO2A status of circulating tumor cells and
corresponding primary tumors
Twenty-six CTC+ patients were further evaluated for
ERBB2 and TOP2A status by FISH in at least one CTC.
Before systemic treatment, CTCs from three HER2+ pri-
mary tumors were evaluated. It is of importance that
none of them showed HER2 amplification in CTCs.
Among patients with HER2- tumors, 24 patients were
classified as having HER2- CTCs. Only one case with
p17-CTCs was detected.
Among 26 CTC+ patients analyzed, two cases showed
TOP2A-amplified CTCs whereas the remaining patients
had TOP2A- CTCs. TOP2A status was available in 11
corresponding primary tumors. Among patients with
TOP2A- primary tumors, seven of them showed TOP2A-
CTCs whereas one had TOP2A-amplified CTCs and
another had p17-CTCs. In contrast, three TOP2A-
amplified primary tumors had TOP2A- CTCs. Neither of
the TOP2A-amplified CTC patients showed HER2 co-
amplification. There was no association between HER2
or TOP2A CTC status and the corresponding primary
tumor. In addition, baseline clinical-pathological
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Figure 2 Distribution of CTCs percentages and CTC count in samples. (a) Distribution of circulating tumor cell-positive (CTC+) percentages
in the three tubes collected at baseline and sequential blood samples. Dark gray: one tube is CTC+; medium gray: two tubes are CTC+; and light
gray: three tubes are CTC+. (b) Stratification of CTC+ patients according to the CTC count in three groups at baseline and sequential blood
samples. Dark gray: at least five CTCs; medium gray: two to four CTCs; and light gray: one CTC. AT, adjuvant therapy; NAT, neoadjuvant therapy.
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characteristics were not linked to the HER2 and TOP2A
status in CTCs. (data not shown).
Circulating tumor cell characterization after a systemic
treatment
After three cycles of AT, 13 patients (34.2%) had CTCs.
In the biomarker analysis, ER expression in four out of
six CTC+ patients was found. Notably, one of the ER-
CTCs was detected in a patient who had an ER+ pri-
mary tumor but no CTCs before systemic therapy. With
regard to PR expression, significant PR staining was
detected in three out of five CTC+ patients. Interest-
ingly, after three cycles of AT, one of the PR+ CTC
cases that came from a PR+ tumor had PR- CTCs at
baseline. EGFR+ CTCs were detected in five cases; one
patient initially had EGFR+ CTCs, whereas four (11.1%)
cases were EGFR- at baseline.
Significantly, 25 (69.4%) cases were still classified as
having EGFR- CTCs after three cycles of chemotherapy
and six (16.6%) cases later were classified as having
EGFR- CTCs. In addition, HER2 status and TOP2A sta-
tus were evaluated in seven CTC+ patients. In six of
them, HER2 and TOP2A genes were normal. Among
patients with HER2- tumors, discordant HER2 and
TOP2A expression was found as one case was classified
as having HER2 and TOP2A-co-amplified CTCs.
At the end of treatment, CTCs were detected in 17
(44.7%) of the patients. ER and PR expression of CTCs
was detected in three patients (8.5%) and one patient
(2.8%), respectively. Remarkably, two patients classified
Table 1 Circulating tumor cell status in relation to patient characteristics
CTC+, number (percentage) CTC-, number (percentage) P value (c2)
Age, years
≤ 50 14 (41.2) 20 (58.8)
> 50 32 (50) 32 (50) NS
Histology
Ductal 40 (47) 45 (53)
Others 6 (46.2) 7 (53.8) NS
Clinical tumor size
≤ 2 cm 25 (54.3) 21 (45.7)
> 2-5 cm 15 (39.5) 23 (60.5)
> 5 cm 6 (42.9) 8 (57.1) NS
Clinical nodal status
cN0 28 (47.5) 31 (52.5)
cN+ 11 (34.4) 21 (65.6) NS
Unknown 4 (57.1) 3 (42.9)
Grade
I 8 (38.1) 13 (61.9)
II 15 (44.1) 19 (55.9)
III 20 (55.5) 16 (44.5)
Unknown 3 (42.9) 4 (57.1) NS
Hormonal status
HR+ 35 (46.7) 40 (53.3)
HR- 11 (47.8) 12 (52.2) NS
HER2 status
HER2+ 3 (21.4) 11 (78.6)
HER2- 43 (51.2) 41 (48.8) 0.046
p53 status
p53+ 26 (51) 25 (49)
p53- 7 (50) 7 (50)
Unknown 13 (39.4) 20 (60.6) NS
Ki-67 percentage
≤ 14% 20 (52.6) 18 (47.4)
> 14% 26 (43.3) 34 (56.7) NS
HR+ indicates hormone receptor-positive: estrogen receptor-positive/progesterone receptor-positive (ER+/PR+), ER+/PR-, or ER-/PR+. HR- indicates hormone
receptor-negative. A total of 98 patients were included in this study. Information on clinical nodal status was available in 91 out of 98 (92.8%) patients and
information on p53 status was available in 65 out of 98 (66.3%) patients at the time of study analysis. P values were determined by chi-squared tests. All
statistical tests were two-sided. CTC, circulating tumor cell; HER2, human epidermal growth receptor 2; NS, not significant.
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as having ER- CTCs at the completion of NAT had ER+
CTCs in the baseline sample and the corresponding pri-
mary tumor. In the 36 analyzed samples for EGFR
expression, one case of EGFR+ CTCs persisted whereas
seven (19.4%) later were classified as having EGFR-
CTCs. Among cases that were initially classified as hav-
ing EGFR- CTCs, 25 (69.4%) were still negative for
EGFR expression and three were classified as having
EGFR+ CTCs in the last blood sample.
In nine patients with CTCs still detectable, HER2 and
TOP2A status was evaluated. Neither HER2 nor TOP2A
amplification was found in any CTCs. Two of the corre-
sponding primary tumors carried HER2 amplification,
and seven were classified as HER2- tumors.
CTC status before and after systemic treatment is
shown in Figure 3. It is notable that only around 30% of
the patients switched their CTC status after systemic
treatment. The predominant group of patients in the
adjuvant and neoadjuvant setting is the group of
patients with CTCs-negative before and after the sys-
temic treatment.
Breast cancer subtypes and circulating tumor cell
biomarker profile
To address the clinically relevant need to identify sub-
groups of patients within luminal, HER2-amplified, and
triple-negative tumors, we correlated biomarker expres-
sion in CTCs with the three major distinct molecular
BC subtypes (Table 2). Note that there was a statistically
significant association between only luminal tumors and
higher risk of EFGR+ CTCs (P = 0.03).
Discussion
To our knowledge, this study represents the largest ana-
lysis evaluating a set of five biomarkers in CTCs from
sequential blood samples of patients with non-metastatic
BC. In our work, we found a slightly higher detection
rate in a similar amount of blood in comparison with
those other studies using the CellSearch System (Veri-
dex, LLC) before any treatment [13,25,26]. Besides, dif-
ferences in the CTC count between the baseline
samples and the post-treatment samples were not
observed. However, owing to the small number of
patients in each treatment group, our analysis was not
sufficiently powered to draw any definitive conclusion in
this endpoint.
Our observations indicate that phenotyping/genotyp-
ing analysis of CTCs is highly dependent on the detec-
tion rate in three different tubes and the low number of
cells captured in the non-metastatic setting. Of note, the
threshold of at least one CTC has been used before as a
prognostic factor in patients with non-metastatic BC
[12,13,26], reflecting that CellSearch shows similarly low
CTCs counts in this setting. Optimization of CTC assays
for high-throughput processing will be required to allow
a comprehensive characterization of CTCs and large-
scale clinical trials that use this emerging technology
[27].
Several studies have addressed the correlation between
CTC status and clinical-pathological parameters, but
reported observations are still controversial. Lang and
colleagues [25] found that CTCs were more frequently
found in patients with HER2+ tumors, whereas other
researchers have not found any association between the
CTC status and HER2+ tumors [13,14]. In this study,
CTC+ cells were found more frequently in patients with
HER2- tumors, whereas other classic clinical-pathologi-
cal parameters studied did not show a correlation with
CTC status.
Non-detectable CTCs were observed in patients who
were younger than 50 years old had primary tumors
with HER2 amplification and G1-G2, and the higher risk
was in the G1-G2 group. As in the metastatic setting
[28], patients with poor prognostic factors had non-
detectable CTCs. Such apparently contradictory results
may be explained, in part, by the acquisition of
mesenchymal antigens during the epithelial-mesenchy-
mal transition (EMT) which facilitate the process of
invasion and the metastatic cascade [29]. EMT-derived
CTCs may have modulated their phenotype and
acquired mesenchymal-like properties difficult to detect
with the currently used detection methods [30]. As a
result, patients with non-detectable CTCs and poor
prognostic factors might represent a subset of patients
with partial or complete EMT phenotype instead of an
unequivocal undetectable CTC population.
Intriguingly, less than 35% of our population did not
change their CTC status, suggesting that CTC popula-
tion follows a pattern of neutral drift dynamics. This
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Figure 3 Monitoring circulating tumor cell (CTC) status before
and after systemic treatment. Statuses are divided into four
groups: (1) CTC+/CTC+: CTC+ before and after treatment; (2) CTC
+/CTC-: CTC+ before but CTC- after treatment; (3) CTC-/CTC-: CTC-
before and after treatment; and (4) CTC-/CTC+: CTC- before but CTC
+ after systemic treatment. Pie charts show the percentages of
patients in (a) the adjuvant therapy (AT) group and (b) the
neoadjuvant therapy (NAT) group.
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finding diverges with those of previous data [12,14] that
reported a lower incidence of CTC detection rate after
systemic treatment, especially in those patients who had
received anti-HER2 therapies [14,31]. This discrepancy
may be explained, at least in part, by the fact that we
analyzed 30 mL instead of 7.5 mL and because only
14.3% of our patients received trastuzumab as part of
their treatment.
In concordance with the study by Fehm and collea-
gues [17], our findings showed that ER and PR expres-
sion in CTCs were not correlated with ER or PR
expression in the primary tumor. Heterogeneous CTC
subpopulations with different HR phenotypes coexisting
in the same blood sample were observed. Remarkably,
an RNA-based method is not able to evaluate individual
cells and detect heterogeneity among a CTC population,
whereas the IF approach provides an additional biologi-
cally relevant characterization of different CTC subpo-
pulations. Thus, it could be speculated that distinct HR
expression in CTCs in the same patients might, in part,
explain differences in response to both endocrine and
chemotherapy treatments, although this association
needs to be further characterized.
Changes of ER/PR phenotype or persistence of CTC
phenotypes other than the primary tumor phenotype
was also observed in our study in the samples after
treatment. As all of the patients with sequential samples
received chemotherapy, it cannot be excluded that drug-
induced changes and clonal selection may be influenced
by the interaction of CTCs with chemotherapy.
EGFR protein was expressed in 27% of CTCs at base-
line and did not correlate with clinical and pathological
parameters except for HR+ tumors. Preclinical data have
provided evidence that cross-talk between growth factor
receptor (GFR) and ER pathway [32] may mediate the
development of endocrine therapy resistance in HR+ dis-
ease, although EGFR expression has been widely related
to triple-negative BC tumors. The proposed biological
mechanisms to explain how GFR signaling results in
endocrine therapy resistance are conflicting [33-35].
Thus, we hypothesized that EGFR+ CTCs might repre-
sent a potential negative biomarker of response to cer-
tain anti-cancer agents, including endocrine therapy in
patients with HR+ BC.
Besides, less than 25% of the EGFR+ CTC patients
became EGFR- CTC after treatment, suggesting that
conventional agents like chemotherapy or even trastuzu-
mab eradicate partially EGFR+ CTC subpopulations. We
fully acknowledge that our results should be interpreted
with caution because the sample size is limited and the
small numbers of events limit our conclusions.
HER2 overexpression of CTCs in patients with BC has
been well characterized in recent studies [14,15]. Discre-
pancies between HER2 status in CTCs and their corre-
sponding primary tumors have been described in patients
with early and metastatic BC [14,36]. In our study, the rate
for HER2-amplified CTCs detected by FISH was null at
baseline, which differs from the HER2+ CTC rate reported
by other groups using an IF approach. The lack of HER2+
CTCs may be influenced by the fact that CTC populations
are heterogeneous, and analyzing such a small number of
CTCs may underestimate HER2+ populations. Besides,
CTCs with (2+) HER2 IF staining remain unresolved and
could justify partially HER2- CTCs. The optimal HER2
testing performance in CTCs has not been validated yet.
Although IHC was the original method of assessment for
HER2 status, IHC or IF alone cannot be recommended
now for determining anti-HER2 treatment.
Table 2 Biomarker circulating tumor cell profile in relation to breast cancer subtypes
Triple-negative number (percentage) Luminal number (percentage) HER2+ number (percentage) P value
ER+ CTCs 1 (16.7) 7 (63.6) 2 (66.7) NS
ER- CTCs 5 (83.3) 4 (36.4) 1 (33.3)
PR+ CTCs 1(50) 8 (33.3) 0 (0) NS
PR- CTCs 1(50) 16 (66.7) 1 (100)
EGFR+ CTCs 2 (11.1) 24 (35.8) 1 (7.7) 0.03
EGFR- CTCs 16 (88.9) 43 (64.2) 12 (92.3)
HER2+ CTCs 0 (0) 0 (0)a 0 (0) Unable to determine
HER2- CTCs 8 (100) 16 (100) 2 (100)
TOP2A+ CTCs 1 (12.5) 1 (6.3)a 0 (0) NS
TOP2A- CTCs 7 (87.5) 15 (93.7) 2 (100)
aPolysomy 17-circulating tumor cell (17p CTC). The three breast cancer subtypes are triple-negative (estrogen receptor-negative [ER-], progesterone receptor-
negative [PR-], and human epidermal growth factor receptor 2-negative [HER2-]), luminal (ER+ and/or PR+ and HER2-), and HER2 (HER2-amplified tumors). P values
were determined by chi-squared tests. All statistical tests were two-sided. ER+ CTCs, estrogen receptor-positive circulating tumor cells; ER- CTCs, estrogen
receptor-negative circulating tumor cells; PR+ CTCs, progesterone receptor-positive circulating tumor cells; PR- CTCs, progesterone receptor-negative circulating
tumor cells; EGFR+ CTCs, epidermal growth factor receptor-positive circulating tumor cells; EGFR- CTCs, epidermal growth factor receptor-negative circulating
tumor cells; HER2+ CTCs, human epidermal growth factor receptor 2-positive circulating tumor cells; HER2- CTCs, human epidermal growth factor receptor 2-
negative circulating tumor cells; NS, not significant; TOP2A+ CTCs, topoisomerase 2a-positive circulating tumor cells; TOP2A- CTCs, topoisomerase 2a-negative
circulating tumor cells.
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Previous studies have demonstrated that amplification
of TOP2A in BC is not confined to those who are con-
comitantly HER2-amplified, suggesting that a proportion
of HER2- patients exhibit TOP2A alterations [9,37]. Our
findings that two TOP2A-amplified CTCs come from
HER2- primary tumors and that the HER2 gene is not
co-amplified in these CTCs are consistent with previous
observations described in primary BC tissues [37,38].
After three cycles of AT, co-amplification of HER2
and TOP2A in CTCs was observed in one patient with
HER2 and TOP2A- tumor. This finding is consistent
with a shift in tumor genotype and possibly dependency
to alternative signaling pathways in HER2- primary
tumors. As all of the patients included in the sequential
blood analysis received chemotherapy, it cannot be
excluded that HER2 and TOP2A alterations in CTCs
after treatment are influenced, at least in part, by the
interaction with chemotherapy. According to other
research groups, this finding opens up a window of
opportunity because HER2- BCs with co-amplification of
HER2 and TOP2A in CTCs may exquisitely benefit anti-
HER2 agents as well as antracycline-based regimens.
HER2- CTCs were isolated in patients with either
HER2- or HER2+ primary tumors after systemic treat-
ment and trastuzumab therapy when recommended.
This finding suggests that in HER2-amplified BC, HER2-
CTCs may have been selected by trastuzumab therapy.
It is noteworthy that anti-HER2 agents are given in
combination or sequentially [39,40] with chemotherapy,
and the precise mechanism by which HER2- CTCs per-
sist is currently unknown.
Standard predictors for BC treatment selection are HR
expression for endocrine therapy and HER2 status for
anti-HER2 therapy [41]. Among the whole set of bio-
markers evaluated in CTCs, only EFGR+ CTCs were
more frequent in luminal tumors compared with triple-
negative and HER2-amplified tumors. It could be specu-
lated that the association between EGFR+ CTCs and
luminal BC patients is explained, in part, by an increase
of cancer cells expressing EGFR involved in the para-
crine loop in which epidermal growth factor produced
by tumor-associated macrophages increases the invasive-
ness and migration of BC cells that express EGFR [7,8],
although EGFR expression has been widely related to
lower HR levels, higher proliferation, genomic instability,
and HER2 overexpression [42]. Although this associa-
tion needs to be further characterized, luminal tumors
might be more dependent than other BC subtypes on
this mechanism that promotes cell migration and
intravasation.
Conclusions
Our findings exhibit the heterogeneity of biomarker dis-
tribution in CTCs and a lack of correlation with the
primary tumor biomarker profile before and after che-
motherapy. The lack of an association between HR,
HER2, and TOP2A status in CTCs and BC subtypes
may contribute to diversity in gene expression patterns
and clinical outcomes within BC subtypes [43-45]. Bio-
marker characterization in CTCs might become a useful
tool for selecting patients for tailored therapies and tar-
get drug development. However, these findings should
be validated in a larger cohort of patients.
Additional material
Additional file 1: Recovery rates with lower level control numbers
(10, 5, 1 cells). Spiking experiments were performed in cultured cancer
cell lines: MCF-7, SKBB3, MDA-MB 231 and T47D in triplicate. Recovery
rate ranges from 33.3 to 66.6% at 1 cell level, from 33.3 to 66.6 at 5 cells
level and from 53.3 to 73.3% at 10 cells level. Recovery data from single
samples ranged from 15.2% to 173.2% because of the inherent variation
in spiking of low numbers of cells. However, all spiked samples levels
regardless of the low number added, had detectable cells except in one
sample of the level of 1 cell from the SKBR3 cell line.
Additional file 2: Absolute and relative copy numbers of HER-2 and
TOP2A genes in SKBR3, MCF7 cells, after immunomagnetic
separation from blood samples and FICTION analyses.
Abbreviations
AT: adjuvant therapy; BC: breast cancer; CI: confidence interval; CK:
cytokeratin; CTC: circulating tumor cell; EGFR: epidermal growth factor
receptor; EMT: epithelial-mesenchymal transition; ER: estrogen receptor; FISH:
fluorescence in situ hybridization; GFR: growth factor receptor; HR: hormone
receptor; IF: immunofluorescence; IHC: immunohistochemistry; HER2: human
epidermal growth factor receptor 2; NAT: neoadjuvant therapy; OR: odds
ratio; p17: polysomy 17; PR: progesterone receptor; TOP2A: topoisomerase
2α.
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